|
1
|
Khairy G: Anaplastic transformation of
differentiated thyroid carcinoma. Int J Health Sci (Qassim).
3:93–96. 2009.PubMed/NCBI
|
|
2
|
Yu MG, Rivera J and Jimeno C: Poorly
differentiated thyroid carcinoma: 10-year experience in a southeast
asian population. Endocrinol Metab (Seoul). 32:288–295. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molinaro E, Romei C, Biagini A, Sabini E,
Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini
A, Torregrossa L, et al: Anaplastic thyroid carcinoma: From
clinicopathology to genetics and advanced therapies. Nat Rev
Endocrinol. 13:644–660. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagaiah G, Hossain A, Mooney CJ,
Parmentier J and Remick SC: Anaplastic thyroid cancer: A review of
epidemiology, pathogenesis and treatment. J Oncol. 2011:5423582011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siironen P, Hagström J, Mäenpää HO,
Louhimo J, Heikkilä A, Heiskanen I, Arola J and Haglund C:
Anaplastic and poorly differentiated thyroid carcinoma: Therapeutic
strategies and treatment outcome of 52 consecutive patients.
Oncology. 79:400–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Volante M, Collini P, Nikiforov YE,
Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M,
Sobrinho-Simoes M, et al: Poorly differentiated thyroid carcinoma:
The Turin proposal for the use of uniform diagnostic criteria and
an algorithmic diagnostic approach. Am J Surg Pathol. 31:1256–1264.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volante M, Bussolati G and Papotti M: The
story of poorly differentiated thyroid carcinoma: From Langhans'
description to the Turin proposal via Juan Rosai. Semin Diagn
Pathol. 33:277–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Volante M and Papotti M: Poorly
differentiated thyroid carcinoma: 5 years after the 2004 WHO
classification of endocrine tumours. Endocr Pathol. 21:1–6. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asioli S, Erickson LA, Righi A, Jin L,
Volante M, Jenkins S, Papotti M, Bussolati G and Lloyd RV: Poorly
differentiated carcinoma of the thyroid: Validation of the Turin
proposal and analysis of IMP3 expression. Mod Pathol. 23:1269–1278.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smallridge RC and Copland JA: Anaplastic
thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol
(R Coll Radiol). 22:486–497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu
X, Sun H, Shan Z, Wang E, Luo Y, et al: Association of TERT
promoter mutation 1,295,228 C>T with BRAF V600E mutation, older
patient age and distant metastasis in anaplastic thyroid cancer. J
Clin Endocrinol Metab. 100:E632–E637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Landa I, Ibrahimpasic T, Boucai L, Sinha
R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP,
Xu B, et al: Genomic and transcriptomic hallmarks of poorly
differentiated and anaplastic thyroid cancers. J Clin Invest.
126:1052–1066. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nikiforov YE: Genetic alterations involved
in the transition from well-differentiated to poorly differentiated
and anaplastic thyroid carcinomas. Endocr Pathol. 15:319–327. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kunstman JW, Juhlin CC, Goh G, Brown TC,
Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams
C, et al: Characterization of the mutational landscape of
anaplastic thyroid cancer via whole-exome sequencing. Hum Mol
Genet. 24:2318–2329. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jeon MJ, Chun SM, Kim D, Kwon H, Jang EK,
Kim TY, Kim WB, Shong YK, Jang SJ, Song DE and Kim WG: Genomic
alterations of anaplastic thyroid carcinoma detected by targeted
massive parallel sequencing in a BRAF (V600E) mutation-prevalent
area. Thyroid. 26:683–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lissbrant IF, Stattin P, Wikstrom P,
Damber JE, Egevad L and Bergh A: Tumor associated macrophages in
human prostate cancer: Relation to clinicopathological variables
and survival. Int J Oncol. 17:445–451. 2000.PubMed/NCBI
|
|
17
|
Ohno S, Ohno Y, Suzuki N, Kamei T, Koike
K, Inagawa H, Kohchi C, Soma G and Inoue M: Correlation of
histological localization of tumor-associated macrophages with
clinicopathological features in endometrial cancer. Anticancer Res.
24:3335–3342. 2004.PubMed/NCBI
|
|
18
|
Hanada T, Nakagawa M, Emoto A, Nomura T,
Nasu N and Nomura Y: Prognostic value of tumor-associated
macrophage count in human bladder cancer. Int J Urol. 7:263–269.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ryder M, Ghossein RA, Ricarte-Filho JC,
Knauf JA and Fagin JA: Increased density of tumor-associated
macrophages is associated with decreased survival in advanced
thyroid cancer. Endocr Relat Cancer. 15:1069–1074. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Caillou B, Talbot M, Weyemi U,
Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M
and Dupuy C: Tumor-associated macrophages (TAMs) form an
interconnected cellular supportive network in anaplastic thyroid
carcinoma. PLoS One. 6:e225672011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lloyd RV OR, Klöppel G and Rosai J: WHO
Classification of Tumours of Endocrine Organs. 4th edition. WHO;
Geneva: 2017
|
|
22
|
Bejarano PA, Nikiforov YE, Swenson ES and
Biddinger PW: Thyroid transcription factor-1, thyroglobulin,
cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl
Immunohistochem Mol Morphol. 8:189–194. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wreesmann VB, Ghossein RA, Patel SG,
Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH and
Singh B: Genome-wide appraisal of thyroid cancer progression. Am J
Pathol. 161:1549–1556. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Neill JP and Shaha AR: Anaplastic
thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shaha AR, Ferlito A, Owen RP, Silver CE,
Rodrigo JP, Haigentz M Jr, Mendenhall WM, Rinaldo A and Smallridge
RC: Airway issues in anaplastic thyroid carcinoma. Eur Arch
Otorhinolaryngol. 270:2579–2583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al: Sorafenib in radioactive iodine-refractory,
locally advanced or metastatic differentiated thyroid cancer: A
randomised, double-blind, phase 3 trial. Lancet. 384:319–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Donghi R, Longoni A, Pilotti S, Michieli
P, Della Porta G and Pierotti MA: Gene p53 mutations are restricted
to poorly differentiated and undifferentiated carcinomas of the
thyroid gland. J Clin Invest. 91:1753–1760. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fagin JA, Matsuo K, Karmakar A, Chen DL,
Tang SH and Koeffler HP: High prevalence of mutations of the p53
gene in poorly differentiated human thyroid carcinomas. J Clin
Invest. 91:179–184. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ho YS, Tseng SC, Chin TY, Hsieh LL and Lin
JD: p53 gene mutation in thyroid carcinoma. Cancer Lett. 103:57–63.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dobashi Y, Sugimura H, Sakamoto A, Mernyei
M, Mori M, Oyama T and Machinami R: Stepwise participation of p53
gene mutation during dedifferentiation of human thyroid carcinomas.
Diagn Mol Pathol. 3:9–14. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cros J, Raffenne J, Couvelard A and Pote
N: Tumor heterogeneity in pancreatic adenocarcinoma. Pathobiology.
Aug 5–2017.(Epub ahead of print). PubMed/NCBI
|
|
34
|
Riesco-Eizaguirre G and Santisteban P:
Endocrine Tumours: Advances in the molecular pathogenesis of
thyroid cancer: Lessons from the cancer genome. Eur J Endocrinol.
175:R203–R217. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Girgin C, Tarhan H, Hekimgil M, Sezer A
and Gürel G: P53 mutations and other prognostic factors of renal
cell carcinoma. Urol Int. 66:78–83. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim HW, Lee HM, Hwang SH, Ahn SG, Lee KA
and Jeong J: Patterns and biologic features of p53 mutation types
in korean breast cancer patients. J Breast Cancer. 17:1–7. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Horio Y, Takahashi T, Kuroishi T, Hibi K,
Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R, et
al: Prognostic significance of p53 mutations and 3p deletions in
primary resected non-small cell lung cancer. Cancer Res. 53:1–4.
1993.PubMed/NCBI
|
|
38
|
Bolat F, Kayaselcuk F, Nursal TZ,
Yagmurdur MC, Bal N and Demirhan B: Microvessel density, VEGF
expression and tumor-associated macrophages in breast tumors:
Correlations with prognostic parameters. J Exp Clin Cancer Res.
25:365–372. 2006.PubMed/NCBI
|
|
39
|
Ubertini V, Norelli G, D'Arcangelo D,
Gurtner A, Cesareo E, Baldari S, Gentileschi MP, Piaggio G, Nistico
P, Soddu S, et al: Mutant p53 gains new function in promoting
inflammatory signals by repression of the secreted interleukin-1
receptor antagonist. Oncogene. 34:2493–2504. 2015. View Article : Google Scholar : PubMed/NCBI
|
